163 related articles for article (PubMed ID: 37438617)
1. How the COVID-19 pandemic affected bone health: a retrospective, longitudinal study on denosumab persistence from the epicentre of European spreading.
Varenna M; Orsini F; Di Taranto R; Zucchi F; Manara M; Caporali R; Crotti C
Arch Osteoporos; 2023 Jul; 18(1):95. PubMed ID: 37438617
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
[TBL] [Abstract][Full Text] [Related]
3. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
4. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P; Faouzi M; Buclin T; Lamy O;
J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
6. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
8. Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report.
Koiwai H; Kamimura M; Nakamura Y; Takahashi J; Taguchi A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):178-181. PubMed ID: 33019908
[TBL] [Abstract][Full Text] [Related]
9. Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea.
Cha S; Sohn M; Yang H; Yeh EJ; Baek KH; Ha J; Ku H
BMC Musculoskelet Disord; 2024 Jan; 25(1):76. PubMed ID: 38245776
[TBL] [Abstract][Full Text] [Related]
10. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.
Imel EA; Starzyk K; Gliklich R; Weiss RJ; Wang Y; Williams SA
Osteoporos Int; 2020 Dec; 31(12):2413-2424. PubMed ID: 32696118
[TBL] [Abstract][Full Text] [Related]
11. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
[TBL] [Abstract][Full Text] [Related]
12. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
13. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
14. Denosumab Discontinuation.
Sølling AS; Tsourdi E; Harsløf T; Langdahl BL
Curr Osteoporos Rep; 2023 Feb; 21(1):95-103. PubMed ID: 36564572
[TBL] [Abstract][Full Text] [Related]
15. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
16. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider.
Tripto-Shkolnik L; Fund N; Rouach V; Chodick G; Shalev V; Goldshtein I
Bone; 2020 Jan; 130():115150. PubMed ID: 31715340
[TBL] [Abstract][Full Text] [Related]
17. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
[TBL] [Abstract][Full Text] [Related]
18. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.
Grassi G; Chiodini I; Palmieri S; Cairoli E; Arosio M; Eller-Vainicher C
Eur J Endocrinol; 2021 Aug; 185(3):387-396. PubMed ID: 34232124
[TBL] [Abstract][Full Text] [Related]
20. Long-term consequences of osteoporosis therapy with denosumab.
Bandeira F; de Oliveira LB; Bilezikian JP
Arch Endocrinol Metab; 2022 Nov; 66(5):717-723. PubMed ID: 36382761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
